304 related articles for article (PubMed ID: 34593621)
1. Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.
Pinato DJ; Murray SM; Forner A; Kaneko T; Fessas P; Toniutto P; Mínguez B; Cacciato V; Avellini C; Diaz A; Boyton RJ; Altmann DM; Goldin RD; Akarca AU; Marafioti T; Mauri FA; Casagrande E; Grillo F; Giannini E; Bhoori S; Mazzaferro V
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593621
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy.
Craciun L; de Wind R; Demetter P; Lucidi V; Bohlok A; Michiels S; Bouazza F; Vouche M; Tancredi I; Verset G; Garaud S; Naveaux C; Galdon MG; Gallo KW; Hendlisz A; Derijckere ID; Flamen P; Larsimont D; Donckier V
BMC Cancer; 2020 Feb; 20(1):135. PubMed ID: 32075608
[TBL] [Abstract][Full Text] [Related]
3. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
4. Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma.
Pinato DJ; Kaneko T; D'Alessio A; Forner A; Fessas P; Minguez B; Giannini EG; Grillo F; Díaz A; Mauri FA; Fulgenzi CAM; Dalla Pria A; Goldin RD; Pieri G; Toniutto P; Avellini C; Plaz Torres MC; Akarca AU; Marafioti T; Bhoori S; Miró JM; Bower M; Bräu N; Mazzaferro V
JHEP Rep; 2023 Jul; 5(7):100741. PubMed ID: 37274775
[TBL] [Abstract][Full Text] [Related]
5. Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma.
Zheng Z; Ma M; Han X; Li X; Huang J; Zhao Y; Liu H; Kang J; Kong X; Sun G; Sun G; Kong J; Tang W; Shao G; Xiong F; Song J
Acta Biomater; 2023 Feb; 157():337-351. PubMed ID: 36509402
[TBL] [Abstract][Full Text] [Related]
6. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of TACE
Song Z; Guo X; Yin C; Wang Y
Indian J Cancer; 2021; 58(1):57-61. PubMed ID: 33402587
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma.
Montasser A; Beaufrère A; Cauchy F; Bouattour M; Soubrane O; Albuquerque M; Paradis V
Histopathology; 2021 Jul; 79(1):36-46. PubMed ID: 33326644
[TBL] [Abstract][Full Text] [Related]
9. Clinical prognostic value of CD4+CD25+FOXP3+regulatory T cells in peripheral blood of Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma patients.
Li F; Guo Z; Lizée G; Yu H; Wang H; Si T
Clin Chem Lab Med; 2014 Sep; 52(9):1357-65. PubMed ID: 24646790
[TBL] [Abstract][Full Text] [Related]
10. TREM2
Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J
J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359
[TBL] [Abstract][Full Text] [Related]
11. A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE.
Zhang J; Li H; Gao D; Zhang B; Zheng M; Lun M; Wei M; Duan R; Guo M; Hua J; Liu Q; Bai J; Liu H; Zheng J; Yao H
Cancer Biol Ther; 2018 Jun; 19(6):475-483. PubMed ID: 29400599
[TBL] [Abstract][Full Text] [Related]
12. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
[TBL] [Abstract][Full Text] [Related]
13. Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
Hiraoka A; Kumada T; Kudo M; Hirooka M; Koizumi Y; Hiasa Y; Tajiri K; Toyoda H; Tada T; Ochi H; Joko K; Shimada N; Deguchi A; Ishikawa T; Imai M; Tsuji K; Michitaka K;
Dig Dis; 2017; 35(6):602-610. PubMed ID: 29040999
[TBL] [Abstract][Full Text] [Related]
14. [Study on the comparison of postoperative liver injury caused by hepatic arterial perfusion chemotherapy combined with targeted immunotherapy with hepatic arterial chemoembolization combined with targeted immunotherapy for intermediate-and advanced-stage liver cancer].
Li R; Li WL; Yuan GS; Pang HJ; Li Q; Hu XY; Guo YB; Chen JZ; Zang MY
Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1163-1168. PubMed ID: 38238949
[No Abstract] [Full Text] [Related]
15. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
[TBL] [Abstract][Full Text] [Related]
16. Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size.
Lee YK; Jung KS; Kim DY; Choi JY; Kim BK; Kim SU; Park JY; Ahn SH; Han KH; Kim GM; Kim MD; Park SI; Won JY; Lee DY
J Gastroenterol Hepatol; 2017 Feb; 32(2):487-496. PubMed ID: 27503585
[TBL] [Abstract][Full Text] [Related]
17. Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma.
Nishikawa H; Osaki Y; Inuzuka T; Takeda H; Nakajima J; Matsuda F; Henmi S; Sakamoto A; Ishikawa T; Saito S; Kita R; Kimura T
World J Gastroenterol; 2012 Mar; 18(12):1379-84. PubMed ID: 22493552
[TBL] [Abstract][Full Text] [Related]
18. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
19. Changes in immunological function after treatment with transarterial chemoembolization plus radiofrequency ablation in hepatocellular carcinoma patients.
Guan HT; Wang J; Yang M; Song L; Tong XQ; Zou YH
Chin Med J (Engl); 2013; 126(19):3651-5. PubMed ID: 24112158
[TBL] [Abstract][Full Text] [Related]
20. Treatment strategy of adding transcatheter arterial chemoembolization to sorafenib for advanced stage hepatocellular carcinoma.
Lee WC; Hung HC; Lee JC; Wang YC; Cheng CH; Wu TH; Lee CF; Wu TJ; Chou HS; Chan KM
Cancer Rep (Hoboken); 2021 Feb; 4(1):e1294. PubMed ID: 33048465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
